Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Authors: Ramesh K. Ramanathan, Chandra P. Belani, Deepti A. Singh, Michael Tanaka, Heinz-Josef Lenz, Yun Yen, Hedy L. Kindler, Syma Iqbal, Jeff Longmate, Philip C. Mack, Georg Lurje, Regina Gandour-Edwards, Janet Dancey, David R. Gandara

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Purpose

To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC).

Methods

Lapatinib was dosed at 1,500 mg/day orally continuously.

Results

Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7–5.2) months and 2.3 (95% CI: 1.7–5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3–∞) months and 6.2 (95% CI: 5.1–∞) months. EGFR genotyping indicated HCC patients with <20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival.

Conclusions

Lapatinib was well-tolerated. There was evidence of activity in HCC, but therapy with lapatinib did not meet the predefined efficacy rate.
Literature
1.
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRef
2.
Alberts SR, Gores GJ, Kim GP et al (2007) Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc 82:628–637PubMedCrossRef
3.
Shimoda M, Kubota K (2007) Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 13:1500–1504PubMed
4.
Bartlett D, Ramanathan RK, Ben-Joseph E (2008) Gallbladder and bilary cancers. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott, Philadelphia
5.
Berasain C, Castillo J, Prieto J et al (2007) New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27:174–185PubMedCrossRef
6.
Bekaii-Saab T, Williams N, Plass C et al (2006) A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 6:278PubMedCrossRef
7.
Yoon JH, Gwak GY, Lee HS et al (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41:808–814PubMedCrossRef
8.
Sirica A (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5–15PubMedCrossRef
9.
Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663PubMedCrossRef
10.
Thomas MB, Chadha R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067PubMedCrossRef
11.
Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069–3074PubMedCrossRef
12.
Reid A, Vidal L, Shaw H et al (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43:481–489PubMedCrossRef
13.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
14.
Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef
15.
Gautschi O, Huegli B, Ziegler A et al (2007) Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254:265–273PubMedCrossRef
16.
Zhang W, Park DJ, Lu B et al (2005) Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 11:600–605PubMed
17.
Matsuo M, Sakurai H, Saiki I (2003) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2:557–561PubMed
18.
Schiffer E, Housset C, Cacheux W et al (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307–314PubMedCrossRef
19.
Zhu AX, Stuart K, Blaszkowsky LS et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581–589PubMedCrossRef
20.
Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRef
21.
Peréz-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235–5246PubMedCrossRef
22.
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef
23.
Press MF, Finn RS, Cameron D et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861–7870PubMedCrossRef
24.
Van Cutsem E, Lang I, D’haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(May 20 suppl), abstr 2
25.
Weihrauch M, Benicke M, Lehnert G et al (2001) Frequent k-ras-2 mutations and p16INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 84:982–989PubMedCrossRef
26.
Mayoral R, Fernandez-Martinez A, Bosca L et al (2005) Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26:753–761PubMedCrossRef
27.
Mitchell C, Nivison M, Jackson LF et al (2005) Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration. J Biol Chem 280:2562–2568PubMedCrossRef
28.
Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854–857
29.
Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176–13180PubMedCrossRef
30.
Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef
Metadata
Title
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Authors
Ramesh K. Ramanathan
Chandra P. Belani
Deepti A. Singh
Michael Tanaka
Heinz-Josef Lenz
Yun Yen
Hedy L. Kindler
Syma Iqbal
Jeff Longmate
Philip C. Mack
Georg Lurje
Regina Gandour-Edwards
Janet Dancey
David R. Gandara
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0927-7

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Original Article

Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma

Original Article

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer

Original Article

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties

Original Article

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer

Original Article

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits